About Us
Who we are
GenDelph was born from innovative research at the Polytechnic University of Valencia, Spain, where it was developed within the PROS research group at the Valencian Research Institute for Artificial Intelligence (VRAIN).
Our team consists of researchers and professionals united by a shared mission: making high-precision genomic analysis accessible to all. Our R&D is supported by the VRAIN Institute, a top research center with over two decades of software development expertise and ten years of genomic research. We bring together leading specialists in bioinformatics, genetics, software development, data science, and artificial intelligence to deliver cutting-edge genomic solutions.
Our Mission
At GenDelph we are dedicated to democratizing access to genomic analysis while pushing the boundaries of bioinformatics innovation.
We believe that genetic data analysis should be accessible to all, whether for personalized medicine or research purposes. Our approach prioritizes excellence through rigorous analysis quality, robust data privacy and security, and transparent control that empowers professionals at every step of the process.
Quality
Security
Control
In essence, our mission is to empower professionals with complete control over the genomic analysis process while maintaining the highest standards of quality, security, and transparency.
Our Roadmap
past-2022
Research and Development
A decade of genomic research and development at the PROS research group within VRAIN institute at UPV.
2023
SPIN UPV Grant
Awarded the SPIN UPV grant to accelerate product development and market innovation.
2024
Product Development
Development of a SaaS platform and MVP, achieving Technology Readiness Level 7 (TRL 7). Validated in hereditary cancer research through collaboration with the Chilean Hereditary Cancer Group and presented at the ALAG Congress in Mexico.
2025
Spin Off Consolidation
Achieved TRL 9 with expanded clinical validation and commenced commercial operations under Research Use Only (RUO) certification.
2026
Growing and Certifications
FDA certification process initiation and strategic presence planned at key healthcare conferences.
2027
European and International Expansion
Initiate CE marking certification for European market entry.